Effectiveness and safety of repeat dexamethasone for bronchopulmonary dysplasia

J Perinatol. 2021 Aug;41(8):1956-1962. doi: 10.1038/s41372-021-01125-3. Epub 2021 Jun 8.

Abstract

Objective: To describe effectiveness of repeat dexamethasone for bronchopulmonary dysplasia (BPD) and to evaluate adverse effects on growth.

Study design: Retrospective study of infants treated with 1 or 2 courses of dexamethasone for BPD. Effectiveness was defined as successful step-down in respiratory support by end of treatment. Adverse effects on growth were analyzed and compared to untreated controls.

Results: A total of 132 dexamethasone-treated infants were identified. In total, 52% (69/132) of infants treated with initial dexamethasone achieved step-down in respiratory support compared to 38% (20/52) of infants with repeat dexamethasone. Growth trajectory did not significantly differ among infants treated with 1 or 2 courses of dexamethasone compared with controls (weight: P = 0.23, length: P = 0.68, and head circumference: P = 0.77).

Conclusions: Repeat dexamethasone for BPD was less effective in weaning respiratory support compared to initial course. Changes in growth parameters to discharge were comparable between controls and infants treated with 1 or 2 dexamethasone courses.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bronchopulmonary Dysplasia* / drug therapy
  • Dexamethasone / adverse effects
  • Humans
  • Infant
  • Infant, Newborn
  • Infant, Very Low Birth Weight
  • Retrospective Studies

Substances

  • Dexamethasone